At this juncture,
it is evident that vegetable seed has taken a back seat to
field seed when it comes to implementation of biotechnology. I
am talking not only about GMOs but also about other types of
varieties that have been developed through other technological
methods. There are many reasons for this, chiefly the fact
that vegetable crops occupy much smaller acreages than
agricultural crops. This increases the risk factor and makes
it difficult to achieve the scale which ensures a return on
the necessary R&D investment.
Biotechnology
applications will find their way into this sector and we will
eventually succeed in bringing to market nutritionally
enhanced vegetables, but I don't think we are there quite yet.
Some such examples are beginning to emerge, but they remain to
be fully validated.
There has been
much talk about the promises of neutraceuticals, but this area
is still fraught with uncertainties because a great number of
regulatory hurdles will have to be overcome before anyone can
claim tangible health benefits in a new vegetable variety. We
will be expected to support our claims in the most rigorously
scientific manner and to go through a clearance and
registration process akin to what pharmaceutical
products are subjected to, and quite different from the
relatively simple procedure we follow to bring food products
to market.
Modern
technology will certainly bring about innovations and new
types of food products, but I don't believe that this will
happen overnight or without significant hurdles. The costs
associated with the new regulatory process put in place to
bring GMOs to market are causing significant changes in our
industry and creating very high barriers to entry for new
products unless these can be proven to be clearly superior to
existing products.
I also believe
that the vegetables we bring to market are very much perceived
as a food product, with the associated notion of taste and
culinary delight, and I find it difficult to picture that, in
the future, our products would be sold in drugstores and
presented as quasi drugs. |